Degree: Doctor





Nullam viverra aliquet orci quis rutrum. Etiam placerat dui in sapien scelerisque blandit. Nullam fermentum urna at ligula fringilla viverra. Phasellus ut maximus neque. Nullam a mauris vehicula, rutrum sapien quis, volutpat orci. Nam in blandit quam. Maecenas in pharetra dui. Pellentesque vulputate, elit a vulputate suscipit, sapien magna feugiat elit, et porttitor nisl sapien ac nisl. Pellentesque quis convallis magna. Sed nec leo ut odio finibus hendrerit. Sed eleifend purus ex, vel facilisis nulla eleifend ac. Nam mattis gravida ipsum, sed accumsan nunc eleifend sit amet.

Showing 5 latest publications. Total publications: 60
Show all publications
1. 4-Oxoquinolines and monoamine oxidase: When tautomerism matters, Mesiti, F; Maruca, A; Silva, V; Rocca, R; Fernandes, C; Remiao, F; Uriarte, E; Alcaro, S; Gaspar, A Borges, F in EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, ISSN: 0223-5234,  Volume: 213, 
Article,  Indexed in: crossref, scopus, wos  DOI: 10.1016/j.ejmech.2021.113183 P-00T-CGB
Abstract 4-Oxoquinoline derivatives have been often used in drug discovery programs due to their pharmacological properties. Inspired on chromone and 4-oxoquinoline chemical structure similarity, a small series of quinoline-based compounds was obtained and screened, for the first time, toward human monoamine oxidases isoforms. The data showed the N-(3,4-dichlorophenyl)-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide 10 was the most potent and selective MAO-B inhibitor (IC50 = 5.30 +/- 0.74 nM and SI: >= 1887). The data analysis showed that prototropic tautomerism markedly influences the biological activity. The unequivocal characterisation of the quinoline tautomers was performed to understand the attained data. To our knowledge, there have been no prior reports on the characterisation of quinolone tautomers by 2D NMR techniques, namely by H-1-N-15 HSQC and H-1-N-15 HMBC, which are proposed as expedite tools for medicinal chemistry campaigns. Computational studies on enzyme-ligand complexes, obtained after MM-GBSA calculations and molecular dynamics simulations, supported the experimental data.

2. GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure, Fonseca, NA; Gregorio, AC; Mendes, VM; Lopes, R; Abreu, T; Goncalves, N; Manadas, B; Lacerda, M; Figueiredo, P; Pereira, M; Gaspar, M Colelli, F; Pesce, D; Signorino, G; Focareta, L; Fucci, A; Cardile, F; Pisano, C; Cruz, T; Almeida, L; Moura, V; Simoes, S; Moreira, JN in NANO TODAY, 2021, ISSN: 1748-0132,  Volume: 37, 
Article,  Indexed in: scopus, wos  DOI: 10.1016/j.nantod.2021.101095 P-00T-HDG
Abstract Patients with breast or ovarian cancer have not benefited from improved efficacy with pegylated liposomal doxorubicin relative to free drug, likely due to the limited extent of the enhanced permeability and retention (EPR) effect, further compromising drug bioavailability in the tumor. Herein it is hypothesized that targeting nucleolin overexpressed in tumor endothelial cells (readily accessible from the vascular compartment), besides cancer cells, with PEGASEMP (doxorubicin hydrochloride in a lipid-based pegylated nanoparticle functionalized with a 31-aminoacid peptide targeting nucleolin), lessens the dependence on high systemic exposures and EPR effect for successful tumor targeting. This strategy has resulted in improved intracellular tumor bioavailability of doxorubicin, at low systemic exposure, associated with a safe toxicological profile. Levels of cell surface nucleolin dictated the antitumor activity of PEGASEMP against nucleolin-overexpressing solid tumors of diverse histological origin, evidencing a significant growth inhibition of malignant mesothelioma over the standard of care. Those observations were paralleled by an impairment of the nucleolin-positive vasculature and downregulation of typically overexpressed genes. Patient stratification based on nucleolin mRNA expression correlated with prognosis and enabled identification of breast and mesothelioma tumors that may potentially benefit from PEGASEMP. Overall, a novel principle of drug delivery is presented with potential therapeutic impact across nucleolin-overexpressing human cancers. Data Availability: The data that support the findings of this study are available from the corresponding author upon reasonable request.

3. Mapping Chromone-3-Phenylcarboxamide Pharmacophore: Quid Est Veritas?, Mesiti, F; Gaspar, A Chavarria, D Maruca, A; Rocca, R; Martins, EG; Barreiro, S; Silva, R; Fernandes, C; Gul, S; Keminer, O; Alcaro, S; Borges, F in JOURNAL OF MEDICINAL CHEMISTRY, 2021, ISSN: 0022-2623,  Volume: 64, 
Article,  Indexed in: crossref, wos  DOI: 10.1021/acs.jmedchem.1c00510 P-00V-5MW
Abstract Chromone-3-phenylcarboxamides (Crom-1 and Crom-2) were identified as potent, selective, and reversible inhibitors of human monoamine oxidase B (hMAO-B). Since they exhibit some absorption, distribution, metabolism, and excretion (ADME)-toxicity liabilities, new derivatives were synthesized to map the chemical structural features that compose the pharmacophore, a process vital for lead optimization. Structure-activity relationship data, supported by molecular docking studies, provided a rationale for the contribution of the heterocycle's rigidity, the carbonyl group, and the benzopyran heteroatom for hMAO-B inhibitory activity. From the study, N-(3-chlorophenyl)-4H-thiochromone-3-carboxamide (31) (hMAO-B IC50 = 1.52 +/- 0.15 nM) emerged as a reversible tight binding inhibitor with an improved pharmacological profile. In in vitro ADME-toxicity studies, compound 31 showed a safe cytotoxicity profile in Caco-2, SH-SY5Y, HUVEC, HEK-293, and MCF-7 cells, did not present cardiotoxic effects, and did not affect P-gp transport activity. Compound 31 also protected SH-SY5Y cells from iron(III)-induced damage. Collectively, these studies highlighted compound 31 as the first-in-class and a suitable candidate for in vivo preclinical investigation.

4. The synthesis, crystal structure and Hirshfeld analysis of 4-(3,4-dimethylanilino)-N-(3,4-dimethylphenyl)quinoline-3-carboxamide, Gomes, LR; Low, JN; Borges, F; Gaspar, A Mesiti, F in ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2020, ISSN: 2056-9890,  Volume: 76, 
Article,  Indexed in: crossref, scopus, wos  DOI: 10.1107/s2056989020000298 P-00R-R9P
Abstract The structure of the title quinoline carboxamide derivative, C26H25N3O, is described. The quinoline moiety is not planar as a result of a slight puckering of the pyridine ring. The secondary amine has a slightly pyramidal geometry, certainly not planar. Both intra- and intermolecular hydrogen bonds are present. Hirshfeld surface analysis and lattice energies were used to investigate the intermolecular interactions.

5. Searching for new cytotoxic agents based on chromen-4-one and chromane-2,4-dione scaffolds, Gaspar, A Mohabbati, M; Cagide, F Razzaghi Asl, N; Miri, R; Firuzi, O; Borges, F in RESEARCH IN PHARMACEUTICAL SCIENCES, 2019, ISSN: 1735-5362,  Volume: 14, 
Article,  Indexed in: scopus, wos  DOI: 10.4103/1735-5362.251855 P-00Q-84P
Abstract Cancer is a major cause of death worldwide and novel anticancer agents for its better management are much needed. Benzopyrone-based compounds, such as chromones, possess several distinctive chemical and biological properties, of which the cytotoxicity against cancer cells seems to be prominent. In this study, two series of compounds based on chromen-4-one (3-10) and chromane-2,4-dione (11-18) scaffolds were synthesized in moderate/high yields and evaluated for cytotoxicity against HL-60, MOLT-4, and MCF-7 cancer cells using MTT assay. In general, the compounds exhibited moderate cytotoxic effects against the cancer cell lines, among which, a superior potency could be observed against MOLT-4 cells. Chroman-2,4dione (11-18) derivatives had overall higher potencies compared to their chromen-4-one (3-10) counterparts. Compound 13 displayed the lowest IC50 values against HL-60 (IC50, 42.0 +/- 2.7 mu M) and MOLT-4 cell lines (IC50, 24.4 +/- 2.6 mu M), while derivative 11 showed the highest activity against MCF-7 cells (IC50, 68.4 +/- 3.9 04). In conclusion, this study provides important information on the cytotoxic effects of chromone derivatives. Benzochroman-2,4-dione has been identified as a promising scaffold, which its potency can be modulated by tailored synthesis with the aim of finding novel and dissimilar anticancer compounds.